This article was originally published here
Gen Thorac cardiovascular surgery. 2022 May 27. doi: 10.1007/s11748-022-01829-z. Online ahead of print.
OBJECTIVES: This study was conducted to evaluate the outcomes of transcatheter valve-in-valve implantation for degenerated tricuspid bioprosthetic valves with transcatheter aortic valves.
Methods: This retrospective study enrolled all consecutive patients who were considered high risk for reoperations by the cardiac team and who underwent transcatheter valve implantation in the valve for degenerated tricuspid bioprosthetic valves at Tehran Heart Center, Tehran, Iran. All procedures were performed through the transfemoral vein under echocardiographic and fluoroscopic guidance with Edwards SAPIEN transcatheter heart valves (Edwards Lifesciences, Irvine, CA).
RESULTS: Ten patients underwent successful transcatheter valve implantation in the valve in the tricuspid position without any major complications or the need for emergency surgery. The mean age was 54.1 ± 17.1 years and 8 patients were female. The median follow-up was 19.5 months (16-32.25 months). The mean time between the last tricuspid valve replacement and transcatheter valve implantation was 4.9 ± 2.2 years. The bioprosthetic valves were Hancock in three patients, Mosaic in the other three patients and Biocor, Pericarbon, Perimount and Epic in the other patients. After the procedure, clinical and functional status improved significantly in all patients. The mean transvalvular gradient decreased from 6.75 ± 2.66 mm Hg to 2.85 ± 0.89 (P
CONCLUSIONS: In high-risk patients, transcatheter valve-in-valve implantation appears to be a safe and minimally invasive alternative to reoperations for bioprosthetic degenerated tricuspid valves.